
Download and complete the Enrollment and Prescription Form and fax to: 855-423-0011
Strongly recommended by AAD and AAAAI guidelines as a systemic therapy for moderate-to-severe atopic dermatitis in adult patients1,2
Your eligible patients can get additional support from the
Adbry® Advocate® Program by calling 844-MYADBRY (844-692-3279) between 8 ᴀᴍ–8 ᴘᴍ ESTOr, choose one of the following enrollment options:
LEO Pharma Inc. is committed to helping ensure that patients
can access and initiate therapy when prescribed Adbry, including through the Adbry® Advocate® Program. Restrictions apply.See Full Terms, Conditions, and Eligibility Rules.
aThe initial dose of Adbry may be shipped either to your office or to the patient after submission of a completed Enrollment and Prescription Form or annual Healthcare Provider eRx Program Certification Form, as applicable, and Patient Authorization. A program representative will coordinate shipment to a patient, which may extend delivery time. Patients who have been initiated on therapy with samples are not eligible for Rapid Access Product.
bAdditional terms, conditions, and eligibility rules apply. Enrollment in Adbry Advocate is not required to obtain copay support. For all other patient support programs, enrollment in Adbry Advocate is required. Patient or healthcare provider may not seek reimbursement for the benefit received from any party. LEO Pharma reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice.
cPatient is not eligible for the Program if enrolled in any federally or state funded health care program, including but not limited to Medicare (including Medicare Part D), Medicaid, VA, DOD, TRICARE or CHIP.
dIncome eligibility requirements apply. Patient may be required to submit documentation of income and insurance coverage status.
*Program has an annual cap. Program may not be combined with any third-party rebate, coupon or offer.
Actor portrayal.
ADBRY® (tralokinumab-Idrm) injection is indicated for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ADBRY can be used with or without topical corticosteroids.
Please see full Prescribing Information.
1. Davis DMR, et al. J Am Acad Dermatol. 2024:90(2):e43-e56. doi:10.1016/j.jaad.2023.08.102. 2. AAAAI/ACAAI JTF Atopic Dermatitis Guideline Panel, et al. Ann Allergy Asthma Immunol. 2024;132(3):274-312. doi:10.1016/j.anai.2023.11.009.